These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
612 related articles for article (PubMed ID: 21982109)
1. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial. Zhang H; Liu ZL; Sun P; Gu F Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109 [TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series. Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926 [TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Chan WM; Lai TY; Liu DT; Lam DS Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414 [TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Chan WM; Lai TY; Liu DT; Lam DS Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318 [TBL] [Abstract][Full Text] [Related]
6. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461 [TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Yang HS; Kim JG; Kim JT; Joe SG Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P; Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989 [TBL] [Abstract][Full Text] [Related]
9. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization. Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271 [TBL] [Abstract][Full Text] [Related]
10. Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy. Kim H; Lee K; Lee CS; Byeon SH; Lee SC Retina; 2015 Mar; 35(3):481-6. PubMed ID: 25313710 [TBL] [Abstract][Full Text] [Related]
11. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series. Parodi MB; Iacono P; Papayannis A; Kontadakis SD; Cascavilla M; Pierro L; Gagliardi M; Bandello F Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164 [TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up. El Matri L; Kort F; Bouraoui R; Karim B; Chebil A; Chaker N Acta Ophthalmol; 2011 Nov; 89(7):641-6. PubMed ID: 21155980 [TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547 [TBL] [Abstract][Full Text] [Related]
17. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA; Retina; 2008; 28(10):1387-94. PubMed ID: 18827735 [TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A Retina; 2007; 27(4):432-8. PubMed ID: 17420694 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy: results of a 1-year prospective trial. Zhang H; Liu ZL; Sun P; Gu F Retina; 2012 Jun; 32(6):1106-13. PubMed ID: 22481479 [TBL] [Abstract][Full Text] [Related]
20. One-year outcomes of less frequent bevacizumab in age-related macular degeneration. Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]